AbbVie Inc (ABBV)vsSIGA Technologies Inc (SIGA)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
SIGA
SIGA Technologies Inc
$3.03
+0.33%
HEALTHCARE · Cap: $236.39M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 119891% more annual revenue ($64.39B vs $53.66M). ABBV leads profitability with a 9.8% profit margin vs -5.2%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SIGA
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+56.3%
Fair Value
$15.20
Current Price
$3.03
$12.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 33.9%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 49.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : SIGA
The strongest argument for SIGA centers on Price/Book, Operating Margin, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : SIGA
The primary concerns for SIGA are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while SIGA is a turnaround play — different risk/reward profiles.
SIGA carries more volatility with a beta of 0.89 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 35/100) and 10.2% revenue growth. SIGA offers better value entry with a 56.3% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
SIGA Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?